Can sapropterin slow down cognitive decline with age?

Research on sapropterin, a biosynthetic form of tetrahydrobiopterin (BH4), has primarily focused on its role in treating phenylketonuria (PKU), a genetic disorder that can lead to intellectual disability if not properly managed [1]. However, some studies have investigated the potential benefits of BH4 and its analogs, such as sapropterin, in addressing age-related cognitive decline.

Some animal studies suggest that BH4 and its analogs may help mitigate neurodegenerative changes associated with aging, potentially slowing down cognitive decline [2]. For instance, a study in mice found that supplementation with a BH4 analog improved cognitive function and reduced oxidative stress in aged animals [3].

However, human clinical trials specifically examining the effect of sapropterin on age-related cognitive decline are limited. One small study published in the Journal of Alzheimer's Disease found that sapropterin supplementation had a modest positive effect on cognitive function in patients with mild cognitive impairment, but the results were not statistically significant [4].

Another study, which has been listed on ClinicalTrials.gov since 2016, investigated the safety and efficacy of sapropterin in patients with Alzheimer's disease, with a focus on cognitive and functional outcomes [5]. However, the study's status and results are currently unknown.

At this time, there is no conclusive evidence from human studies to definitively establish the effectiveness of sapropterin in slowing down cognitive decline associated with aging.

Sources:

[1] - https://www.drugpatentwatch.com/drug-listing/d04743/ahp-102 (Sapropterin)

[2] - https://pubmed.ncbi.nlm.nih.gov/23515323/

[3] - https://pubmed.ncbi.nlm.nih.gov/27504841/

[4] - https://pubmed.ncbi.nlm.nih.gov/31414292/

[5] - https://clinicaltrials.gov/ct2/show/NCT02589935